KRINGLE PHARMA, INC.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2001-12-21
- Employees
- 13
- Market Cap
- -
Clinical Trials
7
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 3
3 (50.0%)Phase 3 Study of KP-100LI in Subjects With Vocal Fold Scar
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Kringle Pharma, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT05627648
- Locations
- 🇯🇵
Fujita Health University Hospital, Toyoake, Aichi, Japan
🇯🇵Sanno Medical Center, Minato-Ku, Tokyo, Japan
🇯🇵Fukuoka Sanno Hospital, Fukuoka, Japan
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Kringle Pharma, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04475224
- Locations
- 🇯🇵
Spinal Injuries Center, Iizuka, Fukuoka, Japan
🇯🇵Hokkaido Spinal Cord Injury Center, Bibai, Hokkaido, Japan
🇯🇵Japanese Red Cross Kobe Hospital, Kobe, Hyogo, Japan
Phase I/II Study of KP-100IT in Acute Spinal Cord Injury
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Kringle Pharma, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02193334
- Locations
- 🇯🇵
Spinal Injuries Center, Iizuka, Fukuoka, Japan
🇯🇵Hokkaido Chuo Rosai Hospital Sekison Center, Bibai, Hokkaido, Japan
News
No news found